Preclinical studies recently showed that simultaneous blockade of VEGFA and ANG2 inhibits angiogenesis and tumor growth (Brown et al., 2010; Kienast et al., 2013; Schmittnaegel et al., 2017; Wolf and Langmann, 2019). Here, VEGFA is linked to neoplasm.